The effect of the two epipodophyllotoxin derivatives etoposide (VP-16) and teniposide (VM-26) on cell lines established from patients with small cell carcinoma of the lung
- 1 February 1987
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 19 (1) , 16-20
- https://doi.org/10.1007/bf00296248
Abstract
Summary To determine whether there is any difference between the two epipodophyllotoxin derivatives etoposide and teniposide in their therapeutic effect in small cell carcinoma of the lung (SCCL), they were compared against five human SCCL cell lines in vitro. When the two were compared at equimolar concentrations teniposide was found to be 8–10 times more potent than etoposide, both with 1-h incubation and with continuous incubation in a clonogenic assay and in inducing cell cycle perturbations monitored by flow cytometry. Published pharmacokinetic data suggest that this potency difference is not accompanied by an equivalent increase in toxicity. The concentrations used for the 1-h incubation were about 100-fold the concentrations used in the experiments with continuous incubation to obtain the same degree of cell kill for both drugs. This suggests that they should be given according to a continuous rather than an intermittent schedule.Keywords
This publication has 21 references indexed in Scilit:
- Inter-experiment variation and dependence on culture conditions in assaying the chemosensitivity of human small cell lung cancer cell linesEuropean Journal of Cancer and Clinical Oncology, 1987
- Establishment of an etoposide‐resistant human epithelial tumour cell line In vitro: Characterization of patterns of cross‐resistance and drug sensitivitiesInternational Journal of Cancer, 1984
- Etoposide (VP-16) in the treatment of lung cancerCancer Treatment Reviews, 1983
- Long‐term storage of samples for flow cytometric DNA analysisCytometry, 1983
- A Critical Appraisal of the Human Tumor Stem-Cell AssayNew England Journal of Medicine, 1983
- AN EXPERIMENTAL BIOLOGICAL BASIS FOR INCREASING THE THERAPEUTIC INDEX OF CLINICAL CANCER THERAPYAnnals of the New York Academy of Sciences, 1982
- The clinical pharmacology of VM26 and VP16-213Cancer Chemotherapy and Pharmacology, 1982
- Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotoxin glucopyranoside derivativesPublished by Elsevier ,1975
- ARE CELL KINETIC DATA RELEVANT FOR THE DESIGN OF TUMOUR CHEMOTHERAPY SCHEDULES?Cell Proliferation, 1974
- Activity of a new glycosidic lignan derivative (VP 16-213) related to podophyllotoxin in experimental tumorsPublished by Elsevier ,1973